MeSH tree: D12.776.377.715.548.114.224.200
Psoriasis is a common inflammatory skin disease linked to several long-term health conditions, such as heart disease, arthritis and type 2 diabetes, and has a substantial impact on sufferers' quality of life. Although the ...
Feb 4, 2026
0
15
Results from a pilot clinical trial evaluating the safety and feasibility of repeated focused ultrasound-induced blood–brain barrier (BBB) opening combined with the monoclonal antibody drug Avastin (bevacizumab) in patients ...
Feb 3, 2026
0
9
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according ...
Jan 25, 2026
0
13
Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery contributes to our understanding of variability in responses to treatment, even with the most advanced therapies.
Jan 20, 2026
0
11
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in ...
Jan 14, 2026
0
12
The American College of Chest Physicians recently released a new clinical guideline on biologic management in severe asthma. Published in the journal CHEST, the guideline contains seven evidence-based recommendations to provide ...
Jan 13, 2026
0
15
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.
Dec 16, 2025
0
47
Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical ...
Dec 12, 2025
0
19
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
Dec 10, 2025
0
16
